{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:29:56Z","timestamp":1787754596014,"version":"build-2784847793"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ41065"],"award-info":[{"award-number":["2023JJ41065"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00228-025-03855-1","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T14:03:34Z","timestamp":1749305014000},"page":"1217-1227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative efficacy and adverse effects of \u03b23-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis"],"prefix":"10.1007","volume":"81","author":[{"given":"Wenlin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"issue":"1","key":"3855_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","volume":"21","author":"BT Haylen","year":"2010","unstructured":"Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J et al (2010) An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21(1):5\u201326","journal-title":"Int Urogynecol J"},{"key":"3855_CR2","doi-asserted-by":"crossref","unstructured":"Nambiar AK, Arlandis S, B\u00f8 K, Cobussen-Boekhorst H, Costantini E, de Heide M, et al. European Association of Urology Guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol. 2022;82(1):49\u201359.","DOI":"10.1016\/j.eururo.2022.01.045"},{"issue":"5","key":"3855_CR3","doi-asserted-by":"publisher","first-page":"E142","DOI":"10.5489\/cuaj.4586","volume":"11","author":"J Corcos","year":"2017","unstructured":"Corcos J, Przydacz M, Campeau L, Gray G, Hickling D, Honeine C et al (2017) CUA guideline on adult overactive bladder. Can Urol Assoc J 11(5):E142\u2013E173","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"3855_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003985","volume":"212","author":"AP Cameron","year":"2024","unstructured":"Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, Helfand BT et al (2024) The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol 212(1):11\u201320","journal-title":"J Urol"},{"key":"3855_CR5","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2147\/CIA.S252852","volume":"15","author":"G Araklitis","year":"2020","unstructured":"Araklitis G, Robinson D, Cardozo L (2020) Cognitive effects of anticholinergic load in women with overactive bladder. Clin Interv Aging 15:1493\u20131503","journal-title":"Clin Interv Aging"},{"key":"3855_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2019.05.010","volume":"87","author":"G Lozano-Ortega","year":"2020","unstructured":"Lozano-Ortega G, Johnston KM, Cheung A, Wagg A, Campbell NL, Dmochowski RR et al (2020) A review of published anticholinergic scales and measures and their applicability in database analyses. Arch Gerontol Geriatr 87:103885","journal-title":"Arch Gerontol Geriatr"},{"issue":"8","key":"3855_CR7","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/nau.23256","volume":"36","author":"LL Lua","year":"2017","unstructured":"Lua LL, Pathak P, Dandolu V (2017) Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. Neurourol Urodyn 36(8):2123\u20132131","journal-title":"Neurourol Urodyn"},{"key":"3855_CR8","doi-asserted-by":"crossref","unstructured":"Kennelly M, Wielage R, Shortino D, Thomas E, Mudd PN, Jr. Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis. Drugs Context. 2022;11.","DOI":"10.7573\/dic.2022-4-2"},{"issue":"4","key":"3855_CR9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/bju.13882","volume":"120","author":"S Herschorn","year":"2017","unstructured":"Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS et al (2017) Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int 120(4):562\u2013575","journal-title":"BJU Int"},{"issue":"4","key":"3855_CR10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/pharmrev.121.000523","volume":"75","author":"MC Michel","year":"2023","unstructured":"Michel MC, Cardozo L, Chermansky CJ, Cruz F, Igawa Y, Lee KS et al (2023) Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev 75(4):554\u2013674","journal-title":"Pharmacol Rev"},{"issue":"1","key":"3855_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00345-024-04799-4","volume":"42","author":"N Wada","year":"2024","unstructured":"Wada N, Mizunaga M, Abe N, Miyauchi K, Kobayashi S, Ohtani M et al (2024) Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. World J Urol 42(1):113","journal-title":"World J Urol"},{"issue":"5","key":"3855_CR12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2012.05.053","volume":"62","author":"EH Ohlstein","year":"2012","unstructured":"Ohlstein EH, von Keitz A, Michel MC (2012) A multicenter, double-blind, randomized, placebo-controlled trial of the \u03b23-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 62(5):834\u2013840","journal-title":"Eur Urol"},{"issue":"3","key":"3855_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/cpdd.212","volume":"5","author":"Y Abe","year":"2016","unstructured":"Abe Y, Nakano Y, Kanazawa T, Furihata T, Endo T, Kobayashi M (2016) Investigation of drug-drug interactions between ritobegron, a selective \u03b23 -adrenoceptor agonist, with probenecid in healthy men. Clin Pharmacol Drug Dev 5(3):201\u2013207","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"3855_CR14","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s11255-020-02536-5","volume":"52","author":"Z Jian","year":"2020","unstructured":"Jian Z, Yuan C, Li H, Zhang W, Wang K (2020) Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis. Int Urol Nephrol 52(12):2215\u20132221","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"3855_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/luts.12475","volume":"15","author":"W He","year":"2023","unstructured":"He W, Zhang Y, Huang G, Tian Y, Sun Q, Liu X (2023) Efficacy and safety of vibegron compared with mirabegron for overactive bladder: a systematic review and network meta-analysis. Low Urin Tract Symptoms 15(3):80\u201388","journal-title":"Low Urin Tract Symptoms"},{"issue":"1","key":"3855_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/nau.23863","volume":"38","author":"J Wang","year":"2019","unstructured":"Wang J, Zhou Z, Cui Y, Li Y, Yuan H, Gao Z et al (2019) Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn 38(1):22\u201330","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"3855_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/luts.12391","volume":"13","author":"S Mukai","year":"2021","unstructured":"Mukai S, Nomi M, Yamada S, Yanagiuchi A, Sengoku A (2021) The 1-year continuation rate and discontinuation factors of vibegron and mirabegron: a retrospective comparative study in a rehabilitation hospital in Japan. Low Urin Tract Symptoms 13(4):448\u2013455","journal-title":"Low Urin Tract Symptoms"},{"issue":"4","key":"3855_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/luts.12480","volume":"15","author":"H Sato","year":"2023","unstructured":"Sato H, Otsuka S, Tsukada S (2023) Mirabegron versus vibegron in previously untreated female patients with overactive bladder: a randomized, single-clinic, open-label trial. Low Urin Tract Symptoms 15(4):129\u2013138","journal-title":"Low Urin Tract Symptoms"},{"issue":"1","key":"3855_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.eururo.2016.02.030","volume":"70","author":"MJ Drake","year":"2016","unstructured":"Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D et al (2016) Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol 70(1):136\u2013145","journal-title":"Eur Urol"},{"issue":"11","key":"3855_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"BSG Hutton","year":"2015","unstructured":"Hutton BSG, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal\u00e1-L\u00f3pez F, G\u00f8tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"key":"3855_CR21","doi-asserted-by":"crossref","unstructured":"Blaivas JG, Panagopoulos G, Weiss JP, Somaroo C. Validation of the overactive bladder symptom score. J Urol. 2007;178(2):543\u20137; discussion 7.","DOI":"10.1016\/j.juro.2007.03.133"},{"key":"3855_CR22","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Welch VA. Cochrane handbook for systematic reviews of interventions: Cochrane handbook for systematic reviews of interventions; 2019.","DOI":"10.1002\/9781119536604"},{"issue":"3","key":"3855_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","volume":"67","author":"P Abrams","year":"2015","unstructured":"Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R et al (2015) Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol 67(3):577\u2013588","journal-title":"Eur Urol"},{"issue":"4","key":"3855_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4103\/ijabmr.ijabmr_331_23","volume":"13","author":"A Anwar","year":"2023","unstructured":"Anwar A, Gorka V, Chahal HS, Sharma S, Tandon S, Singhal N et al (2023) Comparison of efficacy and safety of a combination of tamsulosin and mirabegron versus tamsulosin alone in the management of overactive bladder in males with lower urinary tract symptoms - TAME-overactive bladder: an open-labeled randomized controlled trial. Int J Appl Basic Med Res 13(4):218\u2013223","journal-title":"Int J Appl Basic Med Res"},{"issue":"1","key":"3855_CR25","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s12325-020-01517-5","volume":"38","author":"H Kakizaki","year":"2021","unstructured":"Kakizaki H, Lee KS, Katou D, Yamamoto O, Sumarsono B, Uno S et al (2021) Mirabegron add-on therapy to tamsulosin in men with overactive bladder: post hoc analyses of efficacy from the MATCH study. Adv Ther 38(1):739\u2013757","journal-title":"Adv Ther"},{"issue":"9","key":"3855_CR26","volume":"15","author":"S Kumar","year":"2023","unstructured":"Kumar S, Tiwari V, Chaurasia DK, Kumar S, Mishra S (2023) A comparative study of solifenacin, mirabegron, and their combination as bladder relaxants in the management of overactive bladder. Cureus 15(9):e45612","journal-title":"Cureus"},{"issue":"2","key":"3855_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.eururo.2018.10.006","volume":"75","author":"HD Mitcheson","year":"2019","unstructured":"Mitcheson HD, Samanta S, Muldowney K, Pinto CA, Rocha BA, Green S et al (2019) Vibegron (RVT-901\/MK-4618\/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. Eur Urol 75(2):274\u2013282","journal-title":"Eur Urol"},{"issue":"2","key":"3855_CR28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/JU.0000000000000807","volume":"204","author":"D Staskin","year":"2020","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr (2020) International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol 204(2):316\u2013324","journal-title":"J Urol"},{"issue":"2","key":"3855_CR29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JU.0000000000003999","volume":"212","author":"D Staskin","year":"2024","unstructured":"Staskin D, Owens-Grillo J, Thomas E, Rovner E, Cline K, Mujais S (2024) Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial. J Urol 212(2):256\u2013266","journal-title":"J Urol"},{"issue":"3","key":"3855_CR30","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/iju.13868","volume":"26","author":"O Yamaguchi","year":"2019","unstructured":"Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O et al (2019) Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: a multicenter, randomized study in Japan (MILAI II study). Int J Urol 26(3):342\u2013352","journal-title":"Int J Urol"},{"issue":"5","key":"3855_CR31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","volume":"73","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T (2018) Vibegron, a novel potent and selective \u03b2(3)-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol 73(5):783\u2013790","journal-title":"Eur Urol"},{"issue":"3","key":"3855_CR32","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2023.05.014","volume":"84","author":"F Farag","year":"2023","unstructured":"Farag F, Sakalis V, Arteaga S, Sihra N, Karavitakis M, Arlandis S et al (2023) What are the short-term benefits and potential harms of therapeutic modalities for the management of overactive bladder syndrome in women? A review of evidence under the auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel. Eur Urol 84(3):302\u2013312","journal-title":"Eur Urol"},{"issue":"1","key":"3855_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/bju.12730","volume":"115","author":"M Rossanese","year":"2015","unstructured":"Rossanese M, Novara G, Challacombe B, Iannetti A, Dasgupta P, Ficarra V (2015) Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a beta(3)-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB). BJU Int 115(1):32\u201340","journal-title":"BJU Int"},{"issue":"3","key":"3855_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.eururo.2017.01.037","volume":"72","author":"C Chapple","year":"2017","unstructured":"Chapple C, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F et al (2017) Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol 72(3):389\u2013399","journal-title":"Eur Urol"},{"key":"3855_CR35","doi-asserted-by":"crossref","unstructured":"Sheng-Mou H, Ho-Hsiung L. Medical treatment of female overactive bladder syndrome and treatment-related effects. J Formos Med Assoc. 2018;117(10).","DOI":"10.1016\/j.jfma.2018.01.011"},{"issue":"5","key":"3855_CR36","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1590\/s1677-5538.ibju.2023.0158","volume":"49","author":"W He","year":"2023","unstructured":"He W, Huang G, Cui W, Tian Y, Sun Q, Zhao X et al (2023) Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. Int Braz J Urol 49(5):535\u2013563","journal-title":"Int Braz J Urol"},{"key":"3855_CR37","doi-asserted-by":"crossref","unstructured":"Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin GL, Mori K, Quhal F, et al. Choosing the most efficacious and safe oral treatment for idiopathic O veractive bladder: a systematic review and network meta-analysis. European urology focus.8(4):1072\u201389.","DOI":"10.1016\/j.euf.2021.08.011"},{"issue":"4","key":"3855_CR38","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.euf.2021.08.011","volume":"8","author":"H Mostafaei","year":"2022","unstructured":"Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin GL, Mori K, Quhal F et al (2022) Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: a systematic review and network meta-analysis. Eur Urol Focus 8(4):1072\u20131089","journal-title":"Eur Urol Focus"},{"issue":"12","key":"3855_CR39","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jclinepi.2012.07.012","volume":"65","author":"EJ Mills","year":"2012","unstructured":"Mills EJ, Thorlund K, Ioannidis JP (2012) Calculating additive treatment effects from multiple randomized trials provides useful estimates of combination therapies. J Clin Epidemiol 65(12):1282\u20131288","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"3855_CR40","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/bimj.201800167","volume":"62","author":"G R\u00fccker","year":"2020","unstructured":"R\u00fccker G, Petropoulou M, Schwarzer G (2020) Network meta-analysis of multicomponent interventions. Biom J 62(3):808\u2013821","journal-title":"Biom J"},{"issue":"1","key":"3855_CR41","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12874-023-01959-9","volume":"23","author":"M Petropoulou","year":"2023","unstructured":"Petropoulou M, R\u00fccker G, Weibel S, Kranke P, Schwarzer G (2023) Model selection for component network meta-analysis in connected and disconnected networks: a simulation study. BMC Med Res Methodol 23(1):140","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"3855_CR42","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S (2013) Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 189(4):1388\u20131395","journal-title":"J Urol"},{"issue":"2","key":"3855_CR43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","volume":"82","author":"S Herschorn","year":"2013","unstructured":"Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE et al (2013) A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the \u03b2\u2083 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 82(2):313\u2013320","journal-title":"Urology"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03855-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03855-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03855-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:36:12Z","timestamp":1757183772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03855-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3855"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03855-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study is deemed to exempt to receive ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All data included in this network meta-analysis were obtained from publicly available and previously published studies. As this study is a secondary analysis of existing data, it did not involve direct interaction with human participants, and thus, informed consent to participate was not applicable. The analysis was conducted in accordance with the ethical guidelines for secondary data research, ensuring that all data were anonymized and used solely for the purpose of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}